Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab ( (GMAB) ) has shared an announcement.
Genmab A/S, the Copenhagen-headquartered biotech group specializing in antibody-based therapies for cancer and serious diseases, operates across North America, Europe and Asia Pacific and has eight approved antibody medicines backed by a robust late-stage clinical pipeline. Its platforms span bispecific antibodies, antibody–drug conjugates and other next-generation modalities targeting transformative treatments.
On February 23, 2026, Genmab reported initial transactions under a share buy-back program launched on February 17, 2026 to repurchase up to 342,130 shares for up to DKK 725 million to meet Restricted Stock Unit obligations. Between February 18 and 20, 2026, the company bought 63,000 shares for a total of DKK 115.2 million, lifting its treasury position to 2,678,851 shares, or 4.17% of share capital, signaling ongoing capital management while remaining within EU market abuse “safe harbour” rules.
The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, it has built a broad portfolio of antibody-based formats, including bispecific antibodies, ADCs and immune-modulating therapies, with eight approved medicines and a strong late-stage clinical pipeline.
Average Trading Volume: 1,672,300
Technical Sentiment Signal: Buy
Current Market Cap: $17.69B
For a thorough assessment of GMAB stock, go to TipRanks’ Stock Analysis page.